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Abstract: BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of
anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of
interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on
the body composition and serum lipid and inflammatory parameters among severe psoriatic patients.
METHODS: Thirty-five severe psoriatic patients were enrolled. Twenty-two received secukinumab
and 13 received ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation
and 6 months later, laboratory examinations measuring metabolic and inflammatory panels and
body composition analyses were performed. RESULTS: After 6 months, a significant reduction was
observed in psoriasis area severity index (p < 0.001) from 18 to 0, in c-reactive protein (p < 0.001)
from 6.6 to 4.00 mg/L, in low-density lipoprotein-cholesterol (p = 0.004) from 3.69 to 3.19 mmol/L,
and an improvement in high-density lipoprotein-cholesterol (p = 0.022) from 1.31 to 1.40 mmol/L.
Median baseline body mass index was 32.80 kg/m2. The body composition parameters did not show
any significant changes. CONCLUSIONS: Anti-interleukin-17 therapy of severe psoriatic patients
does not cause significant changes in body composition parameters. Improvements in the lipid and
inflammatory parameters might have a beneficial effect on patients’ cardiometabolic status. This
effect might be detectable in high-risk obese psoriatic patients.
Keywords: psoriasis; body composition; interleukin-17 inhibitor; metabolic syndrome; obesity
1. Introduction
Psoriasis is a chronic autoinflammatory disorder mediated by Thelper1 and Thelper17
(Th1 and Th17) cells, and it affects 2–3% of the population worldwide [1]. The aetiology
of the disease is multifactorial, and the combination of a genetic predisposition with
environmental trigger factors (drugs, stress, infection, and obesity) is responsible for disease
development [2]. Psoriasis primarily affects the skin and the nails. It is common to also
affect the joints in the form of psoriatic arthritis [3]. The main cytokines currently known to
be involved in disease development are tumour necrosis factor (TNF), interferon-gamma
(IFN-γ), interleukin-12 (IL-12), IL17A-F, IL-22, and IL-23 [4].
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Severe cases of psoriasis are often accompanied by metabolic syndrome, obesity,
diabetes mellitus, and cardiovascular diseases based on shared immunopathogenetic
pathways, and these comorbidities may impact the patients’ health-related quality of life
and mortality [5]. Thus, untreated severe psoriasis may reduce life expectancy by up to five
years [6]. A meta-analysis showed that the prevalence of metabolic syndrome was 2.2 times
higher among psoriatic patients than among non-psoriatic controls [7]. Ferdinando et al.
studied 97 psoriatic patients for metabolic syndrome and compared them to 97 controls.
Higher values of systolic blood pressure, body mass index (BMI), fasting glucose, waist
circumference, and angina pectoris frequency and lower levels of high-density lipoprotein-
cholesterol (HDL-cholesterol) were measured among psoriatic patients [8].
The human body can be divided into two main compartments: body fat mass (BFM)
and fat-free mass (FFM). In terms of sex and age, there may be significant individual
differences in the distribution of the compartments. Approximately 80% of the body is
FFM, which mainly includes visceral and skeletal muscle mass (SMM) and bone tissue,
which is approximately 7% and total body water (TBW), which is 60–70%. TBW can be
further divided into 30% intracellular water (ICW) and 70% extracellular water (ECW).
The ratio of ECW and TBW is an important indicator of body water balance. Body cell
mass (BCM) is defined as the sum of cells in the muscles, internal organs, and central
nervous system that are active in metabolism [9]. Additional indices can be calculated
from parameters specific to fat-free mass, body fat, and muscle mass by using an analogue
method similar to that used for calculation of BMI. In these formulas, we can calculate the
fat free mass index (FFMI), body fat mass index (BFMI) and skeletal muscle mass index
(SMMI) by using the equation of parameter (kg)/height in metres2. These indices, which
also include the BMI, allow for a comparison of parameters regardless of height.
In clinical practice, detailed body-composition analyses can be assessed using a bioelec-
trical impedance analyser (BIA), and they are based on the different electrical conductivities
of different tissues. Impedance consists of electric resistance and reactance. Phase angle
(PA) describes the phase shift between total voltage and total electric current. A higher
PA value corresponds to a higher integrity of the cell membrane. High PA values are
most commonly found in healthy individuals with strong cell membranes and high BCM,
while lower PA values indicate that cells cannot store energy, and the cell membrane is
thinner [10]. BIA examinations are simple, inexpensive, reproducible, and do not require
qualified staff. Also, they are based on the use of nonionizing radiation that makes this
method suitable for follow-up tests. The only known risk of BIA is that arrhythmia can
develop in patients with pacemakers or implantable cardioverter defibrillators. Therefore,
the analyses should be conducted with caution in this patient group [11].
In this self-controlled study, our aim was to determine the long-term (six-month)
effect of novel anti-IL-17 therapies (secukinumab and ixekizumab) on body composition,
serum metabolic parameters (fasting glucose, total cholesterol, HDL-cholesterol, low-
density lipoprotein-cholesterol (LDL-cholesterol), triglyceride, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT)), and serum
inflammatory parameter c-reactive protein (CRP).
2. Materials and Methods
This study was conducted in the Department of Dermatology, Venereology, and
Dermato-Oncology of Semmelweis University, Budapest, Hungary. Body-composition
analyses were performed at the First Department of Surgery and Interventional Gastroen-
terology of Semmelweis University, Budapest, Hungary. Statistical analyses were assessed
at the Department of Health Economics, Corvinus University of Budapest, Hungary. The
study was performed between September 2019 and March 2021, and each patient was
followed-up for 6 months. Approval was obtained from the Regional Institutional Scientific
and Research Committee of Semmelweis University, Budapest, Hungary (licence number:
154/2019, date of approval: 12 September 2019.), and the study meets all the requirements
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of the Declaration of Helsinki. All enrolled patients were informed about the process of the
study and signed patient consent forms.
2.1. Study Design
The effectiveness of the anti-psoriatic therapy was measured by dermatological disease
severity and health-related quality of life scales: the psoriasis area severity index (PASI)
and dermatology life-quality index (DLQI) [12]. These parameters were assessed twice:
before starting treatment and after 6 months.
We enrolled patients with very severe skin symptoms that greatly decreased their
health-related quality of life (PASI > 15 and DLQI > 10). Moreover, patients were included
who received ineffective topical and/or systemic therapies for a minimum of 3 months
prior to IL-17 treatment. Our patients had several other comorbidities and were receiving
other medications not related to psoriasis. Patients’ lifestyle and medications remained
unchanged throughout the follow-up period, and no new therapy was allowed.
During the laboratory examinations, we determined the serum metabolic parameters
(fasting glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, ALT, AST,
and GGT) and serum CRP. Among the patients who received antidiabetic therapies, we
also measured the haemoglobin A1c% (HbA1c %) levels. Blood samples were taken after
8 h of fasting before therapy initiation and, in a similar fashion, after 6 months of therapy.
Laboratory parameters were determined by an autoanalyzer (Beckman Coulter AU 5800
Chemistry Analyzer, Tokyo, Japan) according to the manufacturer’s instructions.
During our study, detailed body-composition analyses were performed to determine
the following parameters: body weight, BMI, FFM, soft lean mass, body fat mass (BFM),
body fat percent (BFP), SMM, TBW, extracellular (EC) water, intracellular (IC) water, ECW
ratio, protein content, mineral content, body cell mass, bone mineral content, visceral fat
area, and phase angle. All patients were measured using the same InBody 770 (InBody
Co., Ltd. model number: BPM040S12FXX, 15, Heugam-gil, Ipjang-myeon, Seobuk-gu,
Cheonan-si, Chungcheongnam-do 331-824, Republic of Korea) bioelectrical impedance
analyser after 6 h of fasting before treatment initiation and, in a similar fashion, after
6 months always at the same time.
Subgroup analyses were also performed as to whether the type of IL-17 inhibitor
and previous biologicals have an impact on the results. The generated subgroups are the
following: severe psoriatic patients who received ixekizumab therapy, severe psoriatic
patients who received secukinumab therapy, severe psoriatic patients who previously
received anti-TNF therapy, and severe psoriatic patients who previously received ustek-
inumab treatment.
2.2. Dosing Regimen of Anti-IL-17 Therapies
Secukinumab was administered at the labelled dose, with 300 mg subcutaneously
administered in weeks 0, 1, 2, 3, and 4 and then every 4 weeks. Ixekizumab was also
administered at the labelled dosing, with 160 mg subcutaneously administered in week 0;
80 mg administered in weeks 2, 4, 6, 8, 10, and 12; and then 80 mg administered every
4 weeks.
2.3. Evaluation of Data
Taking into account the small sample size and skewed distribution of data, median
values and interquartile ranges (IQRs) of the examined parameters (clinical, laboratory,
and body-composition values) were calculated before therapy initiation and after 6 months.
Differences between the initial and 6-month follow-up periods were analysed by the
nonparametric Wilcoxon signed-rank test. Subgroups of patients were compared by using
Mann–Whitney U test. The relationship of baseline and 6-month values was also tested by
Spearman's correlations. All analyses were carried out using IBM SPSS Statistics version 25
software. A p-value of < 0.05 was considered statistically significant.
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3. Results
3.1. Patients’ Characteristics
Baseline patients’ characteristics can be found in Table 1.
Table 1. Descriptive characteristics of severe psoriatic patients treated with interleukin-17 inhibitors.
Patients’ Comorbidities N (%) or Median (IQR)




Age (years) 49 (37–62)
Disease duration (years) 22 (13–27)
BMI (kg/m2) 32.8 (27.14–37.97)





BMI, body mass index; IQR, interquartile range.
Thirty-five adult patients with severe plaque-type psoriasis were enrolled in the
study (21 men and 14 women). At the time of enrolment, the median age of patients
was 49 (37–62) years, and the median disease duration time was 22 (13–27) years. Overall,
18 patients (51.42%) from the study population had psoriatic arthritis verified by a rheuma-
tologist. All enrolled patients at the time of enrolment had very severe skin symptoms;
the median PASI score was 18.0 (14–30), and the median DLQI score was 17.0 (10–27).
Six patients (17.14%) were bionaïve; they had not received any biologic therapies, yet
they had received topical corticosteroid and/or methotrexate (MTX) or acitretin treatment.
Twenty-nine patients (82.86%) received one of the anti-IL-17 medications, secukinumab
or ixekizumab, after being unsuccessfully treated with systemic traditional and biologic
therapies. Unsuccessful treatment was determined as primary inefficacy or loss of drug
efficacy in the form of worsening the psoriatic skin and joint symptoms. Before changing
the treatment regimen, a minimum of three months of ineffective treatment were required.
Among the previously used systemic therapies were MTX, acitretin, cyclosporine, TNF
blockers (adalimumab, infliximab, etanercept), and IL-12/23 antagonist (ustekinumab). In
these cases, anti-IL-17 therapies were introduced as second- or third-line systemic biologic
therapies. In this real-world study, the allocation of the applied therapeutic monoclonal
antibody was determined by the different physicians who were treating the patients; thus,
it was completely random which interleukin-17 inhibitor therapy they were receiving. The
allocation was also based on the S3 European and the relevant national guidelines and the
access to the current medicinal product.
The presence of metabolic syndrome occurred in eighteen patients (51.42%), with
elevated fasting glucose levels (≥100 mg/dL) in 18 patients (51.42%), low HDL-cholesterol
levels (≤40 mg/dL) in 12 patients (34.28%), and elevated triglyceride levels (≥150 mg/dL)
in 15 patients (42.85%). Eleven patients (31.42%) were on antihypertensive treatment,
6 patients (17.14%) were on antihypertensive and antidiabetic treatments, 7 patients (20%)
were on antihypertensive and statin therapies, and 3 patients (8.57%) were on antihyper-
tensive, antidiabetic and statin treatments. When measured, 21 patients (60%) had elevated
CRP (>5 mg/L).
3.2. Clinical and Laboratory Findings
Changes in the clinical and laboratory parameters can be found in Table 2.
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Table 2. Changes in clinical and laboratory parameters of severe psoriatic patients treated with
interleukin-17 inhibitors.




PASI (0–72) 18.00 (14–30) 0.0 (0–4) <0.001
DLQI (0–30) 17.00 (10–27) 0.0 (0–1) <0.001
Laboratory Characteristics
CRP (mg/L) 6.60 (3.20–15.00) 4.00 (2.10–5.60) <0.001
ESR (mm/h) 17.00 (5–37) 7.00 (4–22) 0.004
HDL-cholesterol (mmol/L) 1.31 (1.16–1.53) 1.40 (1.25–1.60) 0.022
LDL-cholesterol (mmol/L) 3.69 (2.75–4.24) 3.19 (2.27–3.83) 0.004
Total cholesterol (mmol/L) 5.40 (4.40–6.50) 5.26 (4.30–6.20) 0.161
Triglyceride (mmol/L) 1.52 (1.11–2.00) 1.50 (1.10–2.38) 0.116
Fasting glucose (mmol/L) 5.60 (4.80–6.30) 5.22 (4.70–6.40) 0.640
AST (U/L) 24.00 (19–35) 24.00 (18–28) 0.207
ALT (U/L) 24.00 (18–43) 24.00 (17–34) 0.011
GGT (U/L) 31.00 (21–65) 28.00 (20–60) 0.120
PASI, psoriasis area severity index; DLQI, dermatology life-quality index; CRP, c-reactive protein; ESR, erythrocyte
sedimentation rate; HDL-cholesterol, high-density lipoprotein-cholesterol; LDL-cholesterol, low-density lipoprotein-
cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase.
Thirteen patients (37.14%) received ixekizumab, and 22 patients (62.86%) received
secukinumab therapy. After six months, we observed significant improvement in both
skin symptoms and health-related quality of life. The PASI score was reduced (p < 0.001)
from a median value of 18.00 to a median value of 0.0, and the DLQI value also improved
(p < 0.001) from a median value of 17.00 to a median value of 0.0.
A dramatic improvement of skin and joint inflammation, measured by PASI and
DLQI scores, was accompanied by significant improvements in CRP and ESR. The median
value of CRP was reduced (p < 0.001) from 6.60 mg/L to 4.00 mg/L, and the median
value of ESR was reduced (p = 0.004) from 17.00 mm/h to 7.00 mm/h. Among the
metabolic parameters, we observed statistically insignificant improvements in the fasting
glucose, total cholesterol, triglyceride, and GGT levels. Transaminases (AST and ALT)
remained stable during the six months. The cardioprotective HDL-cholesterol levels
significantly improved (p = 0.022) from a median value of 1.31 mmol/L to 1.40 mmol/L,
and the atherogenic LDL-cholesterol levels significantly decreased (p = 0.004) from a
median value of 3.69 mmol/L to 3.19 mmol/L after six months of effective anti-IL-17
treatment. Interestingly, of the few patients who suffered from diabetes, HbA1c% levels
were statistically significantly worsened. This may be due to diet failure.
3.3. Body-Composition Analyses
Body-composition measurements can be seen in Table 3.
Only a small number of patients, 3 of 35, had normal BMI. Thirty-two patients
(91.42%) were overweight (BMI > 25.0 kg/m2), of which 21 patients (60%) were obese
(BMI > 30.0 kg/m2). The median baseline body weight was 97.00 (75.70–111.00) kg, and
the median baseline BMI was 32.80 (27.14–37.97) kg/m2. An elevated (>0.39) ECW ratio
was observed in 5 patients (14.28%), while a <7◦ phase angle was found in 32 patients
(91.42%). After six months of effective anti-IL-17 treatments, we did not find any significant
differences in the examined body-composition parameters. We observed a slight decrease
in the median value of the body weight, body-fat percent, visceral fat area, body cell mass,
fat-free mass, FFMI, and SMMI. The median value of the TBW, ECW ratio, phase angle,
and total body score remained stable.
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Table 3. Body-composition parameters of severe psoriatic patients treated with interleukin-17 inhibitors.
Characteristics Baseline Median (IQR) 6-Month Follow-UpMedian (IQR)
p-Value (Wilcoxon
Signed-Rank Test)
Body weight (kg) 97.00 (75.70–111.00) 96.70 (77.40–112.20) 0.269
BMI (kg/m2) 32.80 (27.14–37.97) 32.80 (27.21–38.18) 0.439
Fat-free mass (kg) 55.20 (49.60–69.70) 54.60 (48.6–70.60) 0.895
FFMI (kg/m2) 20.17 (18.76–21.88) 20.00 (18.32–22.46) 0.631
TBW (L) 40.60 (36.40–51.10) 40.60 (36.20–51.80) 1.000
Protein (kg) 10.80 (9.70–13.70) 10.70 (9.40–14.00) 0.741
Minerals (kg) 3.67 (3.09–4.71) 3.61 (3.25–4.75) 0.405
Body fat mass (kg) 33.30 (23.10–47.20) 33.30 (24.20–46.70) 0.548
BFMI (kg/m2) 10.99 (7.87–17.22) 11.15 (8.08–17.86) 0.605
Body fat percent (%) 37.10 (28.90–47.60) 36.90 (29.00–47.30) 0.885
Skeletal muscle mass (kg) 30.80 (27.30–39.10) 30.40 (26.40–40.50) 0.727
SMMI (kg/m2) 11.21 (10.30–12.11) 11.09 (10.15–12.61) 0.556
ECW ratio 0.38 (0.38–0.39) 0.38 (0.38–0.39) 0.984
Phase Angle (◦) 5.60 (5.00–6.00) 5.60 (5.30–6.10) 0.214
Visceral fat area (cm2) 165.50 (115.20–229.20) 164.20 (110.70–220.80) 0.524
Body cell mass (kg) 36.0 (32.20–45.20) 35.60 (31.20–46.60) 0.741
Bone mineral content (kg) 3.06 (2.48–3.86) 2.95 (2.583.91) 0.561
ECW (L) 15.70 (13.90–19.80) 15.70 (13.90–19.50) 0.698
ICW (L) 25.10 (22.50–31.50) 24.90 (21.80–32.60) 0.709
InBody Score 65.0 (53.0–72.0) 65.0 (54.0–73.0) 0.777
BMI, body mass index; FFMI, fat-free mass index; TBW, total body water; BFMI, body fat mass index; SMMI, skeletal
muscle mass index; ECW ratio, extracellular water ratio; ECW, extracellular water; ICW, intracellular water.
3.4. Comparing Body Composition and Laboratory Parameters between Subgroups of Patients
Treated with Secukinumab or Ixekizumab
We compared the effect of the two drugs on body composition and laboratory pa-
rameters. There were no significant differences between secukinumab and ixekizumab
therapy in body composition parameters neither at the baseline nor at the sixth month of
the applied therapies. In the case of the laboratory parameters, only the baseline ALT was
significantly higher in the ixekizumab group with no other significant differences.
3.5. Comparing Body-Composition Parameters between Subgroups of Patients Previously Treated
with Anti-TNF or Ustekinumab Therapy
In our study population, the anti-tumor necrosis factor or ustekinumab therapy were
used before interleukin-17 inhibitor treatment among patients who were not bionaïve. The
impact of the previously used therapies on the observed parameters were also statistically
analyzed. The number of patients who received anti-TNF, ustekinumab, and systemic non-
biological therapies or were bionaïve, respectively, were 8 (22.87%), 15 (42.87%), 6 (17.13%),
and 6 (17.13%).
Body composition and laboratory parameters were not influenced by the previously
used therapies in our study.
3.6. Correlation Analysis of Clinical, Body-Composition, and Laboratory Parameters
Spearman’s test revealed weak correlation between changes of PASI and CRP (0.133).
Weak reverse correlation could be detected between changes of CRP and HDL-cholesterol
levels (−0.21) (Table 4).
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Change (N = 35)
HDL-cholesterol
(mmol/L)
Change (N = 35)
LDL-cholesterol
(mmol/L)
Change (N = 33)
PASI (0–72) Change
(N = 35) - 0.133 0.006 −0.031 0.046
CRP (mg/L)
Change(N = 35) - - 0.424 * −0.210 0.054
ESR (mm/h)








- - - - -
PASI, psoriasis area severity index; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; ESR, erythro-
cyte sedimentation rate; HDL-cholesterol, high-density lipoprotein-cholesterol; LDL-cholesterol, low-density
lipoprotein-cholesterol; * p < 0.05.
4. Discussion
Psoriasis and obesity are connected through the human leukocyte antigen-class
I allele (HLA-Cw6) locus and alpha-ketoglutarate-dependent dioxygenase (FTO) gene
rs9939609 [13,14]. The common key molecules that link metabolic syndrome and psoriasis
are TNF, IL-17, CRP, leptin, and adiponectin [8,15]. IL-17 is one of the central molecules
of the Th17/IL-23 axis that interferes with hepatic steatosis in nonalcoholic fatty liver
disease (NAFLD), and insulin signalling and IL-17R expression correlate with insulin
resistance [16,17]. Forty-seven percent of the psoriatic patients had NAFLD shown by
ultrasound, while ratio in the age-sex-BMI adjusted healthy control group of NAFLD
was only 28% [18]. IL-17 also increases TNF- and lipopolysaccharide (LPS)-induced IL-6
and C-C chemokine ligand 20 (CCL20) production and upregulates IL-17RA expression
in 3T3-L1 adipocytes [19]. In human bone-marrow mesenchymal cells, IL-17A inhibits
the differentiation of adipocytes and the expression of adipokines, while in differentiated
adipocytes, it amplifies lipolysis. Among obese psoriatic patients, lower levels of leptin
and adiponectin can be measured; moreover, a higher PASI score corresponds to a lower
adiponectin level [20–22]. Systemic inflammation, which causes persisting symptoms of
psoriasis, has several indicators, for example, serum level of CRP, HDL-cholesterol, and
Apolipoprotein-A-I. Apolipoprotein-A-I concentration is significantly lower in patients
with psoriasis compared to non-psoriatic, healthy controls [23]. The concentration of
HDL-cholesterol is reciprocally proportional with the systemic inflammation.
During “psoriatic march”, Th17-produced IL-17 cytokines play an important role in the
development of psoriasis, insulin resistance, and obesity that may finally lead to atheroscle-
rotic cardiovascular diseases, acute coronary syndrome, and stroke. The latest biologic
therapies, such as secukinumab and ixekizumab, target these cytokines. Secukinumab is
a fully human monoclonal antibody (mAb), and ixekizumab is a humanized IgG4 mAb.
TNF, the other central cytokine in psoriatic development, belongs to the Th1 line. The effect
of anti-TNF therapies on body weight is well documented. Adalimumab and infliximab
therapies significantly increased body weight and BMI among psoriatic patients [24,25].
Methotrexate therapy, due to its hepatotoxicity, may lead to non-alcoholic fatty liver disease.
Therefore, liver transaminases should be monitored closely in these patients [26]. In the
presence of obesity, methotrexate therapy should be used with caution [27]. In the case of
the effect of other systemic biologic antipsoriatic therapies, Gisondi et al. compared the
effect of ustekinumab and infliximab on body weight changes among plaque-type psoriatic
patients. After seven months of treatment, infliximab showed a significant increase in mean
body weight and BMI compared with patients treated with ustekinumab [28]. In the post-
hoc analysis of the phase III VOYAGE 1 and 2 studies, guselkumab showed higher efficacy
than adalimumab, and it was consistent across different body-weight groups [29]. In the
phase III UltIMMA-1 and 2 studies, rizankizumab showed consistently higher efficacy com-
pared to ustekinumab in all examined body-weight groups [30]. In the case of anti-IL-17
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therapies, such data are limited, and their effect on body composition and metabolic param-
eters are controversial. A post-hoc analysis of FIXTURE-ERASURE-SCULPTURE studies
included 3010 patients who were treated with secukinumab, etanercept, or placebo and
followed-up for 52 weeks. After 52 weeks, secukinumab reduced the high-sensitivity CRP
(hs-CRP), uric acid levels, and BMI values but had no effect on plasma glucose, lipid, and
liver enzyme parameters [31]. In another study, waist circumference, BMI, blood pressure,
fasting glucose, total cholesterol, HDL-and LDL-cholesterol, triglyceride, ALT, AST, and
creatinine levels were determined among psoriatic patients with metabolic syndrome who
received methotrexate or secukinumab therapy for 12 months. In the secukinumab group,
significant changes were not observed in the parameters, and in the methotrexate group, a
significant increase was observed in liver enzymes [32]. In a retrospective study, Wang et al.
examined the effect of secukinumab on 99 psoriatic patients during a 24-week treatment
and found that hs-CRP was significantly reduced, while body weight and BMI were signifi-
cantly increased at week 24 [33]. In the UNCOVER studies, significant changes were not
observed in body weight or serum lipid and glucose parameters after 60 weeks [34].
Our work is a real-life study in which significant improvements were observed in the
disease-related dermatological parameters, PASI and DLQI, as well as the inflammatory
parameter CRP after six months of anti-IL-17 treatment. In the metabolic panel, statisti-
cally significant improvements were not observed for fasting glucose, total cholesterol,
triglyceride, and GGT levels, while statistically significant improvements were observed
for HDL-cholesterol and LDL-cholesterol levels. This is partly due to the reduction of
the generalized inflammation as a consequence of the strong anti-inflammatory effect of
interleukin-17 inhibitors and partly due to the direct effect of the monoclonal antibody. In
mouse experiments, treatment with anti-interleukin-17A antibody significantly reversed
the effect of imiquimod-induced changes in the liver biomarkers related to injury as well
as protein/lipid metabolism; however, treatment with interleukin-17A further aggravated
them through the NF-kB pathway [35,36]. HDL-cholesterol and albumin levels were
improved in the anti-interleukin-17 treated group.
Although it is a limited comparison, data from the FIXTURE-ERASURE-SCULPTURE,
the UNCOVER, and two retrospective studies of Wang et al. and Gisondi et al. show that
lower values of baseline total cholesterol levels and higher values of baseline triglyceride
levels were measured than in our study population. In the case of the baseline HDL-
cholesterol levels, values higher than ours were only found in the UNCOVER studies.
The highest baseline LDL-cholesterol values were measured in our study compared to
the others [31–34]. Moreover, 60% of our study population was obese. In the previously
mentioned UNCOVER studies and retrospective Wang et al. study, the rate of obese
individuals was less than 8% and almost 40% of the study population. The lower prevalence
of obese patients might have influenced the laboratory findings. In our study population, 27
patients (77.14%) had >100 cm2 visceral fat area, and the maximum was 292.8 cm2. Psoriasis
is associated with metabolic syndrome and obesity, and this association is stronger with
increasing disease severity. Based on Langan et al.’s findings in a population-based study
in the United Kingdom, metabolic syndrome was seen in 32% of patients with mild disease
(BSA ≤ 2%), in 36% of patients with moderate disease (BSA 3–10%), and in 40% of patients
with severe disease (BSA > 10%). The risk of obesity in psoriatic patients increases with
the severity of the skin disease: a 14% increased chance of obesity was found with mild
psoriasis, a 34% increased chance of obesity was found with moderate psoriasis, and a
66% increased chance of obesity was found with severe psoriasis [37]. There is a clear
association with abdominal obesity; with increasing degree of abdominal obesity, the risk
of having major cardiac event, stroke, or myocardial infarct also increases [38]. Based on
the 1995 WHO report in our study population, 13 female patients (37.14%) had >35% BFP,
and 18 male patients (51.42%) had >25% BFP [39]. The average PA value in the healthy
white population is approximately 7 degrees [10]. A total of 91.42% of our study population
had PA values less than 7◦. After six months of anti-IL-17 treatment, we did not find any
significant changes in the body-composition parameters. Comparing the two different IL-17
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inhibitor therapies, there was no significant difference on body-composition and laboratory
parameters. No significant impact of previously used systemic biologic therapies could be
observed in body-composition and laboratory parameters during subgroup analysis.
5. Conclusions
IL-17 inhibitor therapy in severe psoriatic patients does not lead to significant changes
in weight or body-composition parameters. However, improvements that we have seen in
lipid and inflammatory parameters during anti-IL-17 treatment might have a beneficial
effect on comorbidities, especially on the patients’ cardiometabolic status. This may be
more meaningful in severe psoriatic patients who also have metabolic syndrome. These
patients could be identified as a group with higher cardiovascular risk.
Interdisciplinary collaborations with internists are required for appropriate patient
care. Regarding the efficacy of IL17 inhibitor biologicals, further investigations should be
performed on high-risk obese patient groups with metabolic syndrome.
6. Study Limitations
Because of the low patient number, patients were not stratified according to their
comorbidities; diabetes mellitus, hypertension, dyslipidaemia, or metabolic syndrome
may influence treatment efficacy, body-composition, and laboratory parameters. Our
patients had several other comorbidities and were receiving other medications not related
to psoriasis, which is another limitation of the study; however, the patients’ lifestyles
and medications remained unchanged throughout the follow-up period. Although our
subgroup analysis did not reveal it, the previous systemic therapies and their interruption
may have an influence on the observed parameters. Last, this study was a self-controlled
study in which the patients were their own controls.
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Abbreviations
Th T helper
TNF tumour necrosis factor
IFN-γ interferon gamma
IL interleukin
BMI body mass index
HDL-cholesterol high-density lipoprotein-cholesterol
BFM body fat mass
FFM fat-free mass
SMM skeletal muscle mass
TBW total body water
ICW intracellular water
ECW extracellular water
BCM body cell mass
FFMI fat-free mass index
BFMI body fat mass index
SMMI skeletal muscle mass index





GGT gamma glutamyl transferase
CRP c-reactive protein
ESR erythrocyte sedimentation rate
PASI psoriasis area severity index
DLQI dermatology life-quality index
HbA1c% haemoglobin A1c%
BFP body fat percent
IQR interquartile ranges
MTX methotrexate
FTO gene rs9939609 alpha-ketoglutarate-dependent dioxygenase gene rs9939609 variant
NAFLD non-alcholic fatty liver disease
IL-17R interleukin-17 receptor
LPS lipopolysaccharide
CCL CC chemokine ligand
mAb monoclonal antibody
VOYAGE 1 study A study of guselkumab in the treatment of participants with moderate to
severe plaque-type psoriasis
VOYAGE 2 study A study of guselkumab in the treatment of participants with moderate to
severe plaque-type psoriasis with randomized withdrawal and retreatment
UltIMMA-1 study BI 655066 (risankizumab) compared to placebo and active comparator
(ustekinumab) in patients with moderate to severe chronic plaque psoriasis
UltIMMA-2 study BI 655066 versus placebo and active comparator (ustekinumab) in patients
with moderate to severe chronic plaque psoriasis
FIXTURE Safety and efficacy of secukinumab compared to etanercept in subjects
With moderate to severe, chronic, plaque-type psoriasis
ERASURE Efficacy and safety of subcutaneous secukinumab for moderate to severe
chronic plaque-type psoriasis for up to 1 year
SCULPTURE Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to
severe chronic plaque-type psoriasis assessing different
doses and dose regimens
hs-CRP high-sensitivity c-reactive protein
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UNCOVER-1,2 A phase 3 study in participants with moderate to severe psoriasis
UNCOVER-3 A study in participants with moderate to severe psoriasis
NF-kB nuclear factor kappa light chain enhancer of activated B cells
BSA body surface area
WHO World Health Organisation
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